Skip to content

Johannes Kornhuber

Department of Psychiatry and Psychotherapy, University Clinic, Friedrich-Alexander-University of Erlangen-Nürnberg, Schwabachanlage 6, 91054 Erlangen, Germany.

4 papers in the library · 97 citations · publishing 2015-2025

Papers

Novel Psychoactive Substances—Recent Progress on Neuropharmacological Mechanisms of Action for Selected Drugs

Frontiers in Psychiatry August 18, 2017 Zurina Hassan, Oliver G. Bosch, Darshan Singh et al. 62 citations

Human culture involves learning to consume natural or synthetic psychoactive compounds that alter mental states and behavior. After a novel psychoactive substance (NPS) emerges and is experimentally used, its benefits and harms can be estimated, leading to legal classifications ranging from medical use to complete bans. However, banned drugs often continue to be used, allowing better understanding of their properties, and views on a drug can shift from harmful to medically useful. This review summarizes recent neuropharmacological progress on several NPS, including mitragynine, synthetic cannabinoids, dimethyltryptamine, novel serotonergic hallucinogens, cathinones, ketamine, novel dissociatives, gamma-hydroxybutyrate, gamma-butyrolactone, and 1,4-butanediol, highlighting both emerging harm potentials and potential medical applications.

"Herbal seizures"--atypical symptoms after ibogaine intoxication: a case report.

Journal of medical case reports October 31, 2015 Lorenz Breuer, Burkhard S Kasper, Bernd Schwarze et al. 16 citations

A 22-year-old man developed visual memories, nausea, vomiting, and generalized tonic-clonic seizures with additional grand mal seizures after taking a cumulative 38 g dose of ibogaine in two doses. He was treated with midazolam and levetiracetam; drug screenings and brain imaging were negative. Knowledge of ibogaine's side effects has mainly come from reports of cardiovascular complications; seizures are rarely mentioned and experimental findings are inconsistent. It seems that ibogaine acts like a proconvulsive drug at high doses.

The Effect of Digital Mindfulness Interventions on Depressive, Anxiety, and Stress Symptoms in Pregnant Women: A Systematic Review and Meta-Analysis.

European journal of investigation in health, psychology and education September 1, 2023 Monique L Mefrouche, Eva-Maria Siegmann, Stephanie Böhme et al. 15 citations

Digital mindfulness interventions significantly reduce depression and anxiety symptoms during pregnancy, but not stress symptoms. A systematic review and meta-analysis of 13 randomized-controlled trials with 1,373 participants found that digital mindfulness methods lowered depression (effect size g = -0.47) and anxiety (g = -0.41) compared to control groups. The effects were moderated by attrition rate and whether the woman was pregnant for the first time (primiparity). These findings suggest digital mindfulness is a promising approach for managing mental health symptoms in pregnant women.

Brain acid sphingomyelinase controls addiction-related behaviours in a sex-specific way.

Neurobiology of disease March 1, 2025 Liubov S Kalinichenko, Iulia Zoicas, Anne-Marie Bienia et al. 4 citations

Overexpression of acid sphingomyelinase (ASM) in the forebrain affects addiction-related behaviors differently in male and female mice. In males, forebrain ASM overexpression increased alcohol consumption in a free-choice paradigm and reduced conditioned place preference (CPP) for alcohol and cocaine, but not for amphetamine, ketamine, or high-fat/carbohydrate food. In females, it increased binge-like alcohol drinking while moderate consumption remained unchanged, and enhanced CPP for amphetamine but not other substances. These findings suggest ASM plays a sex-specific role in the reinforcing effects of certain addictive substances, offering potential molecular targets for drug- and sex-specific therapies.